Research is increasingly demonstrating that genetic mutations play a significant role in the development of ALS: for example, the C9orf72 gene is one of the most prominent genetic causes of the disease. With the scientific community abuzz about CRISPR/CAS9, a state-of-the-art technology that enables scientists to precisely manipulate and edit genes in living organisms, the […]
Archive for May, 2017
Could state-of-the-art gene editing play a role in correcting genetic mutations linked to the development of ALS?
Deirdre O’Connor and her husband, Floyd, became ALS Canada donors 15 years ago. At the time, they had no personal connection to the cause, but they liked the fact that ALS Canada was a small, cost-effective charitable organization without a lot of overhead. Deirdre’s generosity extends to half a dozen or more organizations she supports […]
For many families, Mother’s Day is a time of celebration and joy. For others, it can be a time of sadness and reflection when there is an empty seat at a once-filled dinner table. For Anna Acheson, Sunday will be the first Mother’s Day she spends without her mother, Margaret. After participating in the 2016 […]
Updated October 5, 2017 Highlights: In May 2017 the United States Food and Drug Administration approved edaravone (also referred to as Radicava and Radicut) for the treatment of ALS. It’s the second ALS drug to be approved in the US. The first drug, riluzole, was approved more than 20 years ago. Radicava became available in […]